Flag Glasensor

About Us

Supervisor: Prof. Julien Reboud

Glasensor has developed a point-of-care biosensor to quantify Adalimumab in human plasma. The biosensor uses heat as an innovative single technology for both the principle technology formolecular recognition and a flow actuation mechanism.


  • Correlation Scatter
  • Dose Response
  • Time To Result
  • Sample Volume
Contact info
For more information, please feel free to contact the team by email at glasensor2019@gmail.com or follow us on Instagram

Glasensor would like to thank BioRad for their expertise and assistance throughout the development of the biosensor.